Jyong Biotech Ltd. Ordinary Shares (MENS) - Stock Analysis

Last updated: Aug 4, 2025

HealthcareClosed

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Jyong Biotech (MENS) has surged from $7.50 to over $23 post-IPO, showing exceptional short-term strength and clear higher highs/lows. Momentum traders targeting quick gains could capitalize on further follow-through, though underlying liquidity and trial risks remain significant.

Loading chart data...

Idea window: 8/4/2025 – 8/11/2025Sector: Healthcare

AI Analyst Overview

Last Price

$3.33

Market Cap

$266.10

1D Return

-3.76%

YTD Return

-15.70%

Loading chart data...

Valuation Metrics

P/E

-200.3

P/B

-11.2

P/S

0.0

EV/EBITDA

—

Div Yield

—

Description

Jyong Biotech Ltd., headquartered in Taiwan, develops plant-derived therapeutics for disorders of the urinary system and advances its programs through subsidiaries including Health Ever Bio‑Tech and Genvace. Its lead candidate is in Phase III for benign prostatic hyperplasia, a second molecule is in Phase II for prostate cancer, and additional compounds remain at the preclinical stage. The company combines in-house development with subsidiary operations to progress its clinical pipeline.

Idea History

Date	Close	Ticker	Company	Summary	Status	P/L
Aug 4	Aug 11	MENS	Jyong Biotech Ltd. Ordinary Shares	Jyong Biotech (MENS) has surged from $7.50 to over $23 post-IPO, showing exceptional short-term strength and clear higher highs/lows. Momentum traders targeting quick gains could capitalize on further follow-through, though underlying liquidity and trial risks remain significant.	Closed	+111.3%

People also watch

Baxter International Inc.

BAX

+7.5%

AtriCure, Inc.

ATRC

+3.8%

Arrowhead Pharmaceuticals, Inc.

ARWR

+18.8%